Brought to you by 
Genzyme acquires rights to three drugs from Bayer HealthCare
29 Apr 2020
Executive Summary
In an agreement funded solely through the achievement of milestones and royalties, Bayer HealthCare has licensed Genzyme exclusive global development and commercialization rights to Campath/MabCampath (alemtuzumab) for multiple sclerosis and B-cell chronic lymphocytic leukemia (CLL), and exclusive worldwide rights to present and future indications of the cancer drugs Fludara (fludarabine) and Leukine (sargramostim).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme acquires rights to three drugs from Bayer HealthCare
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice